Birabresib

DB15189InvestigationalSmall molecule

Birabresib is under investigation in clinical trial NCT02698176 (A Dose Exploration Study With MK-8628 in Participants With Selected Advanced Solid Tumors (MK-8628-006)).

Formula / weight: C₂₅H₂₂ClN₅O₂S · 491.99 g/mol (avg)
Also known as: 2-[(6S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thienol[3,2,-f]-[1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl]-N-(4-hydroxyphenyl)-acetamide
Code names: MK-8628 · OTX015

Resolves to

Compound

UNIIX40LKS49S3CAS202590-98-5ChEMBLCHEMBL3581647ChEBI191051

Structure

InChIKeyGNMUEVRJHCWKTO-FQEVSTJZSA-NSMILESCC1=C(C)C2=C(S1)N1C(C)=NN=C1[C@H](CC(=O)NC1=CC=C(O)C=C1)N=C2C1=CC=C(Cl)C=C1

Targets

P25440BRD2O60885BRD4

What you can answer from here — as of August 30, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

6Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Birabresib, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account